ViewPoints Article: 5 Technologies That Redefines Human Medicine and Therapeutics
Shots: The P-II LIMT study involves assessing of (peg INF-Lambda) Lambda 120/180 μg SC IV qw for 48wks. in ratio (1:1) (N=33) in patients with chronic HDV, testing safety, efficacy & tolerability. In the study, patients received continuous anti-hepatitis B virus nucleos(t)ide analog P-II LIMT study results (120/180mg): mean decline in HDV-RNA (-1.5 log10, -2.4 […]Read More
